The Oncology Nursing Society (ONS) is a professional organization of more than 35,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care. As the main point of contact with patients and families, these nurses influence cancer care in all practice settings. ONS offers multiple ways to share your message with and engage this powerful community. Learn more about how a partnership with ONS can help you reach oncology nurses who are looking for education, products, and services that will help them improve cancer care.
Our nurse members, nurse scientists, and nurse teachers have become known as the standards bearers of advanced cancer care thanks to their dedication to deliver the best possible care, combined with their desire to advance evidence-based research.
Become part of the standard for quality oncology care.
The ONS Corporate Council is an exclusive, high-level opportunity available to a limited group of industry supporters. In the spirit of true partnership, it was created to reinforce your company’s industry leadership and recognize your essential role in advancing the oncology nursing profession.
The investment for this fully integrated sponsorship opportunity is $140,000 per year.
For more information about the Corporate Council please contact email@example.com for more information.
At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, visit http://www.abbvie.com/oncology. For clinical trial details: www.abbvieresearchstudies.com/ONS or www.MMStudyInfo.com.
At Amgen, we are committed to the relentless pursuit of breakthroughs for cancer patients and their families. Visit AmgenOncology.com to learn more.
For more information on Amgen’s pipeline, https://www.amgenoncology.com/pipeline.html.
Clinical Trial specifics can be found at https://www.amgenoncology.com/medical.html.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, hematology, immunology, cardiovascular and neuroscience. Through the Bristol Myers Squibb Foundation, an independent 501(c)(3) charitable organization, we support community-based programs that promote cancer awareness, screening, care and support among high-risk populations in the United States, as well as China, Brazil and sub-Saharan Africa. Our employees around the world work every day to transform patients’ lives through science.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn. Also find out more about our Clinical Trials and Patient Assistance Program.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. For additional information, please visit www.g1therapeutics.com.
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com.
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates, with the potential to improve the treatment of advanced cancers.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Learn more about our patient assistance program.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma. Learn more about our patient assistance program.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases. Learn more about our patient assistance program.
Industry supporters may also join our new Industry Relations Panel, which offers two tiers of support at $50,000 and $25,000 per year. Please contact firstname.lastname@example.org for more information.
Industry Relations Panel members receive:
Industry Relations Panel Members
ONS offers promising opportunities to reach your target audience through our respected conferences, publications, podcasts, educational resources, awards, and member communications. Sponsorships offer an opportunity for your organization to support the needs of oncology nurses while providing essential financial support to ONS initiatives. Please contact the ONS Business Development Team at email@example.com to learn more about how we connect you to our mission.
The ONS Center for Advocacy and Health Policy advocates for the advancement of quality cancer care. The Center elevates the voice of the oncology nurse and provides a forum for collaboration and advocacy at national and local levels.
Program Support Opportunities
ONS and its affiliated corporations seek corporate financial support for oncology nursing education and research programs, health policy initiatives, and communication to professionals and consumers. Corporate funding is guided by the ONS, Oncology Nursing Foundation, and Oncology Nursing Certification Corporation Corporate Support Position, and the Guiding Principles for ONS Policies Related to Corporate Support and Resolving Conflicts of Interest. It is also driven by priorities outlined in our strategic plan, research agenda, and health policy agenda.
Programs and materials submitted for the Oncology Nursing Society Seal of Approval are evaluated by ONS clinical experts, and must meet all review criteria for approval listed in the program guidelines, including consistency with ONS Standards and Guidelines and quality of the educational information. The Oncology Nursing Society Seal of Approval is a valuable symbol of recognition by one of the most respected organizations in cancer care.
ONS Standards and Guidelines provide the latest evidence-based information and guidelines to ensure the best possible outcomes at the highest levels of care. As a leading voice in oncology nursing, ONS is dedicated to providing these resources to nurses on the front line of cancer treatment and patient care.
Apply now for the Oncology Nursing Society Seal of Approval.
Showcase your brand and reach a captive target audience with the below opportunities from ONS.
One-time mailing lists are available to companies seeking to reach our members with information related to oncology nursing and quality cancer care.
ONS has a membership of more than 35,000 RNs and other healthcare professionals who are dedicated to excellence in patient care, education, research, and administration in oncology nursing. Please note that approximately 20–25% of members do not allow for their name and address to be included in the list rental database. As a result, the total number of names available for purchase is approximately 23,000–26,000.
Mailing List Rentals
The ONS mailing list is available to organizations who have relevant information for our oncology nurse membership. Visit the ONS List Rental page or contact InFocus Marketing at firstname.lastname@example.org or 800-708-5478 for more information.
Share your message with more than 35,000 ONS members plus a larger community of nurses who care for patients with cancer through print advertising, digital banner ads, interstitials, and more. For more information on advertising with ONS in 2021, please contact the Townsend Group, a subsidiary of SmithBucklin, or view the 2021 and 2022 ONS Advertising Media Kits.
The Townsend Group
2001 K Street NW
3rd Floor North
Washington, DC 20006
Digital advertising opportunities are available on our website, in select e-newsletters, on ONS Voice (our official news magazine), and on Clinical Journal of Oncology Nursing, and Oncology Nursing Forum (our scholarly journals).
Learn about our unique opportunities for face-to-face engagement with oncology nurses who are looking for education, products, and services that will help them improve cancer care.
47th Annual ONS Congress®
April 27–May 1, 2022
ONS Congress is the association’s signature meeting featuring nursing continuing professional development (NCPD) opportunities, contact hours, five educational learning tracks with expert speakers, opportunities to network and learn at industry events, and share ePoster and oral abstract presentations.
This annual conferences brings together thousands of nurses to learn about the latest treatments and symptom management strategies, expand their professional network, and advance their career. As the main point of contact with patients and their families, these nurses influence cancer care in all practice settings.
Learn about our unique opportunities to engage with oncology nurses who are looking for education, products, and services that will help them improve cancer care.
Exhibit at ONS Congress: Make your plans now to meet with oncology nurses who are leaders on the frontline of cancer care. Share how you can help them provide better patient care, advocate for their patients, take the next step in their career, or take care of themselves so they can be the best nurse they can be. Our learning hall is filled with partners from industry, patient advocacy groups, employers, recruiters, and more. Join this group of oncology leaders who support oncology nurses and improve patient care.
Become a Sponsor: Put your name and logo in front of thousands of oncology nurses and others in the oncology field through ONS Congress sponsorship opportunities. ONS Congress gives you the visibility you need to put your organization front and center. Whether your goal is to increase brand recognition, drive traffic to your booth, or send your company’s message home with each attendee, you will find what you need to meet your goals at ONS Congress. We have a variety of new opportunities available, but if you don’t see what you’re looking for, contact us about creating a custom package to help you make the greatest impact.
Hold an Event: Holding an event at ONS Congress connects you to the nurses who are the main point of contact for patients with cancer and their loved ones. They manage the symptoms of cancer and its treatment, provide patient education, and serve as a consistent point of communication and care throughout the cancer continuum.
Visit our Exhibits and Sponsorship page for more information.
ONS Bridge™ Virtual Conference
September 13 and 15, 2022
ONS Bridge is our premier virtual conference designed to connect nurses in direct-patient care to resources and education at their convenience through a mix of live and on-demand content. ONS Bridge features top-notch educational sessions led by experts in the field. Virtual attendees are able to earn approximately 30 NCPD contact hours, enjoy opportunities to network and learn at industry events, a virtual exhibit hall, and on-demand offerings.
Visit our Exhibits and Sponsorship page for more information.
Each year, ONS grants prestigious recognition to oncology nurses, researchers, and employers who change lives and better their profession. These awards are made possible through the generous support of our industry partners.
ONS is dedicated to the professional development of oncology nurses around the world through a renowned awards program.